

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) A method for altering insulin secretion comprising, contacting a pancreatic islet cell expressing SGK1 with a substance that modulates SGK1.
2. (Original) A method according to claim 1, wherein the expressed SGK1 comprises a selected SNP variant.
3. (Currently Amended) A method of ~~claim 1-2~~ claim 1, wherein the modulator of SGK1 is an inhibitor.
4. (Currently Amended) A method of ~~claim 1-2~~ claim 1, wherein the modulator is an activator of SGK1.
5. (Original) A method of claim 1, wherein the inhibition of SGK1 comprises reversal of the depolarizing effect of glucose, activation of voltage gated Ca-channels and insulin release.
6. (Original) A method according to claim 5, wherein the polymorph SGK1 SNP variant is diagnosed before inhibition.
7. (Currently Amended) A method according to ~~claims 1-4~~ claim 1, characterized by the up-regulation of insulin secretion
8. (Currently Amended) The method of ~~claims 1-4~~ claim 1 wherein the treated subject suffers from symptoms of diabetes mellitus type-2.
9. (Original) A method for reducing glucocorticoid induced diabetes mellitus type-2 in a subject in need of such a treatment by modulating the activity of SGK1 in pancreatic islet cells.

10. (Currently Amended) The method of ~~claim 1-4~~ claim 1, wherein the treated subject has stress induced hyperglycemia.
11. (Currently Amended) The method of ~~claim 1-4~~ claim 1, wherein the treated subject has hypoglycemia .
12. (Original) A method for determining the progression, regression or onset of a disease by measuring the expression of SGK1, comprising taking a sample from the diseased individual.
13. (Original) A method according to claim 12, wherein the SGK1 comprises s a selected SNP variant.
14. (Original) A Pharmaceutical composition comprising an SGK1 inhibiting agent together with a pharmaceutically effective carrier, excipient or diluent.
15. (Original) Use of SGK1 inhibitors selected from the listed compounds having the general formula I or II for the manufacture of a medicament for the treatment of disorders caused by impaired insulin secretion.